Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Frontiers in Oncology|August 27, 2019
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung AdenocarcinomaXiaohong Han, Qiaoyun Tan, Sheng Yang, et al.
BMC Cancer|April 11, 2016
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancerYan Sun, Ying Cheng, Xuezhi Hao, et al.
Translational Lung Cancer Research|January 13, 2023
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohortZihua Zou, Yangchun Gu, Li Liang, et al.
Science China. Life Sciences|May 17, 2026
Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancerWei Zhuang, Hua Bai, Jie Zhao, et al.
The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.
BMC Medicine|February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
Pageof 11